ArticlePharmaceutics2022

Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment.

Hung-Jun Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.